Antitumor agent-151
Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis.
For research use only. We do not sell to patients.
- CAS No.: 3036751-77-3
- Formula: C22H20FN5O
- Molecular Weight:389.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Bone marrow cell | IC50 |
>20 nM
Compound: 7k
|
Cytotoxicity against normal bone marrow cell (unknown origin) assessed as cell proliferation incubated for 72 hrs by CCK-8 assay
Cytotoxicity against normal bone marrow cell (unknown origin) assessed as cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| HL-60 | IC50 |
40.5 nM
Compound: 7k
|
Anti-leukemia activity against human HL-60 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human HL-60 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| K562 | IC50 |
131.8 nM
Compound: 7k
|
Anti-leukemia activity against human K562 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human K562 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| Kasumi 1 | IC50 |
41.1 nM
Compound: 7k
|
Anti-leukemia activity against human Kasumi 1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human Kasumi 1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| MOLM-13 | IC50 |
30.1 nM
Compound: 7k
|
Anti-leukemia activity against human MOLM-13 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human MOLM-13 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| MV4-11 | EC50 |
0.078 μM
Compound: 7k
|
Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 48 hrs by CCK-8 assay
Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 48 hrs by CCK-8 assay
|
[PMID: 38620134] |
| MV4-11 | EC50 |
5.2 μM
Compound: 7k
|
Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 24 hrs by CCK-8 assay
Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 24 hrs by CCK-8 assay
|
[PMID: 38620134] |
| MV4-11 | IC50 |
0.03 μM
Compound: 7k
|
Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human MV4-11 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| OCI-AML2 | IC50 |
39.2 nM
Compound: 7k
|
Anti-leukemia activity against human OCI-AML2 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human OCI-AML2 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| THP-1 | IC50 |
79.7 nM
Compound: 7k
|
Anti-leukemia activity against human THP-1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human THP-1 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
| U-937 | IC50 |
78.2 nM
Compound: 7k
|
Anti-leukemia activity against human U-937 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
Anti-leukemia activity against human U-937 cells assessed as decrease in cell proliferation incubated for 72 hrs by CCK-8 assay
|
[PMID: 38620134] |
In Vitro
Antitumor agent-151 (7k) displays a strong activity for inhibition of other AML cell lines. The IC50 values of Molm13, U937, OCI-AML2, THP-1, HL60, KASSUMI, and K562 cell lines are 30.1 ± 2.3, 78.2 ± 3.1, 39.2 ± 0.9, 79.7 ± 0.3, 40.5 ± 0.8, 41.1 ± 1.7, and 131.8 ± 1.5 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Chemical Information
-
CAS No. 3036751-77-3
-
Molecular Weight 389.43
-
Formula C22H20FN5O
-
SMILES
O=C(C1=C(CCN(C1)CC2=CC(C#N)=CC=C2)N3)N=C3NCC4=CC=C(C=C4)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)